N/A N=40 Insular Inhibitory Neuromodulation to Reduce Cigarette Craving and Alter Brain Function in Smokers
Smoking
Primary: Changes in Cue-induced Cigarette Craving (Post-treatment - Pre-treatment) as Assessed by TCQ
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=12 Physiological Flow of Liquids in Head and Neck Cancer Patients: A Pilot Study
Deglutition Disorders · Oropharynx Cancer
Primary: Number of Participants With Unsafe Swallowing — 9; 4; 3 Participants
Phase 3 N=2,691 Safety of Single and Repeat Treatments of DaxibotulinumtoxinA for Injection for Treatment of Moderate to Severe Glabellar Lines
Glabellar Frown Lines
Primary: Incidence of Treatment Emergent Adverse Events (TEAE) — 831; 267; 118 Participants
Phase 2 N=54 Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Acute Lymphoblastic Leukemia · Lymphoblastic Lymphoma
Primary: Number of Participants With Morphological Complete Response Rate — 27; 20 Participants
Phase 2 N=121 A Study to Assess the Efficacy and Safety of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
Primary: Efficacy Measured by Time to Stand Test (TTSTAND) Velocity in Rises/Second Change From Baseline — -.007; 0.054 Rises/Seconds
Phase 2 N=69 An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis
Lupus Nephritis
Primary: Percentage of Patients With Complete Renal Response (CRR) and Without Any Renal Flares — 51.83; 48.15; 59.49; 57.51 Percentage of participants — p=0.7957
Early Phase 1 N=17 A Dose-Finding Study of AG-348 in Sickle Cell Disease
Sickle Cell Disease
Primary: Number Participants With Most Common Reported Drug Related Adverse Events — 6; 3; 3 Participants
Phase 3 N=154 APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)
MDS
Primary: Complete Response Rate (CR) — 27; 17 Participants
Phase 2 N=493 An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response Over Time — 87.7; 73.4; 77.8; 89.0 percentage of participants
Phase 2 N=11 Carvedilol for the Prevention of Anthracycline/Anti-HER2 Therapy Associated Cardiotoxicity Among Women With HER2-Positive Breast Cancer Using Myocardial Strain Imaging for Early Risk Stratification
Breast Cancer
Primary: Maximum Change in LVEF at 3 Months — 1; -5 change in percent ejection fraction
Phase 2 N=32 Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer
Carcinoma, Non-Small-Cell Lung
Primary: Progression Free Survival (PFS) — 6.6 months
Phase 2 N=252 Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...
Malaria
Primary: Number of Participants With Positive Sensitive Blood Smear (sBS) — 0; 0 Participants
Phase 4 N=168 A Study to Evaluate Androderm®'s Effect on Blood Pressure in Adult Hypogonodal Male Participants
Hypogonadism
Primary: Change From Baseline in 24-hour Average Systolic Blood Pressure (SBP) Obtained at Week 16 — 123.2; 3.5 millimeters of mercury (mmHg)
Phase 4 N=10 Senescent Immunity in Elders and Vaccine Responses (SILVER)
Flu Vaccine
Primary: Hemagglutinin Antigen Inhibition Assay Titers at Baseline — 20; 160; 25; 40 antibody titers
Phase 4 N=14 Exercise Pulmonary Transit Time
Heart Failure, Diastolic
Primary: Pulmonary Transit Time — 2.5 seconds